Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

AD-LINK: Reversing Early Aβ-Driven Network Hyperexcitability

Ziel

Despite decades of research, there is currently no drug capable of preventing Alzheimer’s disease (AD), and ~99% of the drug candidates ultimately fail in clinical trials. This high failure rate is largely due to the lack of reliable preclinical models that enable continuous, longitudinal testing of therapeutic interventions from the earliest, pre-symptomatic stages of the disease.

AD‑LINK is a chronic neurotechnology platform designed to extract high‑resolution neurophysiological signatures of early AD across development and disease progression for longitudinal drug testing. Building on ERC‑funded discoveries showing that microglial dysfunction drives early network hyperexcitability, AD‑LINK addresses a fundamental limitation of current methods: no existing tool can provide stable, months‑long high‑density recordings while also enabling precise, localized perturbation of disease‑relevant pathways in freely moving animals. To meet the distinct needs of different disease stages, we will develop two complementary devices: (1) an ultra‑lightweight Neuropixels 2.0 drive for juvenile mice, enabling continuous tracking of the earliest circuit abnormalities during developmental onset; and (2) an integrated Liquid‑Ephys drive for adult mice, combining high‑density electrophysiology with controlled in situ delivery of soluble factors, allowing causal testing of how targeted interventions modulate — and potentially reverse — pathological circuit states. Through iterative engineering, in vivo validation, IP development, and structured engagement with industrial partners, this ERC PoC will deliver a de‑risked research platform that replaces insensitive behavioral endpoints with precise circuit‑level signatures. By enabling longitudinal, mechanistic analysis of early neuronal dysfunction and its modulation over time, AD‑LINK will strengthen the translational foundations of pre‑clinical AD research, thus aiming to increase success rate of AD drug candidates at clinical trials.

Wissenschaftliches Gebiet (EuroSciVoc)

Dieses Projekt wurde noch nicht bei EuroSciVoc klassifiziert.
Schlagen Sie die Wissenschaftsbereiche vor, die Ihrer Einschätzung nach besonders relevant sind, und helfen Sie uns, unseren Klassifizierungsdienst zu verbessern.

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2026-POC

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

VIB VZW
Netto-EU-Beitrag
€ 150 000,00
Adresse
SUZANNE TASSIERSTRAAT 1
9052 ZWIJNAARDE - GENT
Belgien
Region
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Aktivitätstyp
Research Organisations
Links
Gesamtkosten
Keine Daten

Begünstigte (1)